Suven Life Sciences on Thursday informed the exchanges that it has been granted one product patent from Brazil and one product patent from Eurasia corresponding to new chemical entities. The patent products are for the treatment of disorders associated with neurodegenerative diseases such as Alzheimer’s, attention deficient hyperactivity disorder (ADHD), Parkinson’s, Huntington’s disease, and schizophrenia, among others. The patents are valid through 2023 and 2034, respectively. Shares of Suven Life jumped 1.94 per cent at ₹226.15 on the BSE
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.